While the Cre-driven conditional knockouts limit our ability to treatment directly in Cre-driven spontaneous tumor models, additional studies to confirm the impact of ongoing and treatment-related MyD88-driven signaling in pancreatic cancer on outcome are needed to evaluate this in a more authentic tumor environment. This evidence concerns the gene MYD88 and familial pancreatic carcinoma.